13F Holdings
中文EN

OPK OPKO HEALTH, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 944809 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.3%
TTM net income YoY17.9%
TTM EPS YoY24.0%
Revenue 3-yr CAGR-16.7%
Net income 3-yr CAGR—

Margins

Gross margin46.2%
Operating margin-25.5%
Net margin-29.5%
FCF margin-27.0%
EBITDA margin-8.3%

Returns

ROE-12.2%
ROA-7.6%
ROIC (approx.)-12.4%
Asset turnover0.26x

Leverage & solvency

Liabilities / assets40.6%
Debt / equity0.00x
Current ratio4.97x
Interest coverage2.08x

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$606.88M$713.14M$863.50M$1.00B$1.77B
Cost of revenue$400.94M$494.63M$545.37M$715.98M—
Gross profit$205.94M$218.51M$318.13M$288.22M—
R&D expense$124.03M$105.21M$89.59M$73.89M$76.85M
SG&A expense$223.00M$304.22M$300.56M$372.67M$468.86M
Operating income-$117.41M-$152.06M-$157.02M-$226.25M$18.75M
Interest expense$0$47.47M$13.51M$12.06M$18.88M
Pretax income-$241.36M-$10.36M-$184.32M-$391.52M-$14.03M
Income tax-$15.71M$42.84M$4.44M-$63.50M$15.49M
Net income-$225.68M-$53.22M-$188.86M-$328.40M-$30.14M
EBITDA-$25.78M-$53.89M-$51.72M-$117.60M$97.47M
EPS (basic)-0.30-0.08-0.25-0.46-0.05
EPS (diluted)-0.30-0.08-0.25-0.46-0.05
Weighted avg. shares (diluted)751.13M694.02M751.77M719.06M648.08M
Balance sheet
Cash & equivalents$364.41M$426.58M$95.88M$153.19M$134.71M
Receivables$90.25M$118.02M$123.38M$127.31M$259.64M
Inventory$52.73M$56.80M$65.70M$74.06M$86.50M
Current assets$581.88M$662.09M$309.48M$394.52M$823.01M
PP&E, net$72.81M$70.13M$75.43M$82.88M$79.73M
Goodwill$320.85M$529.25M$598.26M$595.85M$520.60M
Intangibles$446.43M$616.61M$740.28M$823.52M$321.68M
Total assets$1.93B$2.20B$2.01B$2.17B$2.40B
Current liabilities$146.68M$193.10M$200.05M$213.48M$330.01M
Short-term debt$1.74M$437.20M$1.99M$1.72M—
Long-term debt$2.26M$3.00M$50,600$9.29M$205.27M
Total debt$4.00M$440.20M$2.04M$11.01M$205.27M
Total liabilities$663.98M$834.76M$622.48M$605.61M$714.59M
Shareholders' equity$1.27B$1.37B$1.39B$1.56B$1.69B
Net debt-$360.41M$13.62M-$93.84M-$142.18M$70.56M
Cash flow statement
Operating cash flow-$178.54M-$183.49M-$28.20M-$95.19M$38.34M
Capital expenditure$12.28M$25.01M$16.27M$24.58M$32.16M
Free cash flow-$190.82M-$208.50M-$44.47M-$119.77M$6.18M
Investing cash flow$230.30M$352.21M-$18.20M$91.04M$35.95M
Financing cash flow-$118.06M$184.17M-$11.30M$22.97M-$10.35M
Depreciation & amortization$91.63M$98.18M$105.30M$108.66M$78.72M
Stock-based compensation$10.71M$11.05M$11.41M$18.51M$13.63M
Share buybacks$47.04M$90.22M$0$0—

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.